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Abstract
Context: Finding the source of adrenocorticotropic hormone (ACTH)-independent
cortisol-producing adenoma in the patients with subclinical Cushing syndrome (SCS)
and bilateral adrenal nodules is sometimes challenging. Computed tomography (CT) and
positron emission tomography are helpful, but adrenal venous sampling (AVS) is the
gold standard approach. However, interpretation of AVS is important to improve the accuracy of decision-making for surgery. We report a case and review of the literature to
assess the benefit of using adrenal vein cortisol to metanephrine ratio to determine the
source of cortisol production in SCS and bilateral nodules.
Evidence Acquisition: Three authors searched PubMed for data on patients with SCS
who had AVS procedure and measurements of cortisol and catecholamines.
Case Description: A 51-year-old woman with SCS and hypertension crisis presented
to our clinic. Paraclinical investigations revealed that she had an ACTH-independent
cortisol-producing adenoma and her CT scan showed bilateral adrenal nodules. After
AVS, cortisol (high to low) lateralization ratio could not determine the source of cortisol
production but the cortisol to metanephrine ratio localized the source to the left side,
which included the larger nodule according to CT measurements. Left adrenalectomy led
to clinical and paraclinical improvement.
Conclusion: There is a possibility of co-secretion of other steroids accompanied with
cortisol in the setting of ACTH-independent SCS. Moreover, cortisol measurement alone
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and interpretation of AVS results based on cortisol values may not help lateralizing the
source of cortisol production with bilateral adrenal nodules. Therefore, we suggest applying cortisol to metanephrine ratio with the same gradient (gradient > 2.3, highest to
lowest concentration) when the source of cortisol production cannot be determined by
cortisol lateralization ratio.
Key Words: subclinical Cushing, adrenal venous sampling, cortisol to metanephrine ratio

accuracy of AVS for surgical decision-making can be very
important [17, 21].
When AVS is used for evaluation of SCS patients, the
measurements should be performed after an overnight
fast and with low-dose (1-2 mg) or high-dose (8 mg)
dexamethasone the day before the procedure to suppress
ACTH and minimize the effect of stress on cortisol level.
In addition, the correct catheter position is important,
which is based on the adrenal vein (AV) to peripheral vein
(PV) metanephrine ratio. An AV:PV metanephrine ratio
greater than 12 indicates correct adrenal vein position and
successful catheterization [17, 21]. There are 2 usual approaches to lateralize a cortisol-secreting adenoma. The
AV:PV cortisol gradient is one method, with a ratio less
than 3.3 not clinically significant, between 4.1 and 6.4 associated with adrenal hyperplasia, and greater than 6.5
consistent with cortisol-producing adenoma [17, 18]. The
second approach involves a higher to lower cortisol gradient between the 2 adrenal veins. It has been reported
that a gradient greater than 2.3 proves lateralization and
less than 2 is associated with bilateral cortisol production
[17, 21]. However, this is a very narrow window of cortisol
ratios on which to base a surgical decision of which adrenal to remove, and it also does not account for a gradient
between 2 and 2.3. We present a case to justify the role of
cortisol to metanephrine ratio as an alternative approach in
the situation where the current criteria cannot lateralize a
cortisol-producing adenoma.

Methods
We (3 authors) searched PubMed using the keywords
subclinical Cushing syndrome, mild autonomous cortisol
production, adrenal venous sampling for literature that
included patients with bilateral adrenal nodules and SCS
who underwent AVS. We selected cases with information
regarding cortisol and catecholamines (metanephrine,
normetanephrine, epinephrine/adrenaline, and norepinephrine/noradrenaline) levels of peripheral and adrenal
veins. We used the side-to-side adrenal vein cortisol concentration and cortisol to catecholamines ratio ([cortisol/catecholamines in dominant adrenal vein]/[cortisol/
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The increased use of imaging modalities has led to
greater detection of incidental adrenal nodules. Adrenal
incidentalomas are common, approximately 0.2% in the
young and up to 7% in people over the age of 70 [1].
Physicians must differentiate between a nonfunctional
versus hormonally active nodule and between benign
versus malignant nodules, on the basis of imaging and biochemical workup. The majority of adrenal incidentalomas
are benign and nonfunctional; however, subclinical
hypercortisolism is present in approximately 5% to 30%
of adrenal incidentalomas. Subclinical Cushing syndrome
(SCS) is defined by the presence of biochemical autonomous cortisol production without overt symptoms or signs
of hypercortisolism [2, 3] and other terms for this condition is mild autonomous cortisol excess/secretion (MACE/
MACS), or autonomous cortisol secretion (ACS) [4].
Patients with SCS are at increased risk of comorbidities,
such as diabetes, osteoporosis, vertebral fractures, hypertension, dyslipidemia, and obesity [5, 6]. Furthermore,
surgical intervention with an adrenalectomy improves cardiovascular risk and comorbidities, such as hypertension,
diabetes, dyslipidemia, and obesity [7-10].
It is sometimes difficult to ascertain the source of cortisol production in SCS. Although one would tend to think
that the dominant nodule is the one making the excess cortisol, this is often not the case, and the assumption can result in surgical removal of the wrong adrenal. To localize
the source of the excess cortisol production, both imaging methods and selective adrenal vein sampling (AVS)
have been used. Adrenal scintigraphy using iodine-168labeled 19-iodocholesterol [11-13] and fluorine-18-labeled
fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scanning [14]
are applied to localize the source of cortisol production.
Selective venous sampling is another method, which is used
for primary hyperaldosteronism [15], adrenocorticotropic
hormone (ACTH)-independent Cushing syndrome [16,
17], SCS [18], and hyperandrogenism [19]. Although scintigraphy and AVS are reported as acceptable methods to localize the cortisol-producing adenoma [20], these methods
often give discordant findings [21]. Furthermore, surgical
approach based on the nodule size is used [16], but the
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Case Report
A 51-year-old Caucasian woman presented to the outpatient endocrinology clinic for evaluation of bilateral
adrenal masses incidentally diagnosed on CT scan of her
abdomen during workup for uncontrolled vaginal bleeding.
Review of system was positive for intermittent flushing
and hypertensive crisis. On examination, the patient’s
weight was 268 pounds and body mass index was 37.5 kg/
m2. The patient did not have classic features of Cushing
syndrome, such as purple abdominal striae or plethora.
Fasting glucose was 100 mg/dL and her glycated hemoglobin (HbA1c) was 5.5%. An abdominal CT scan from
February 2019 revealed 2.3 cm right and 3.5 cm left side
adrenal nodules (Hounsfield units < 10). On review of a
previous CT scan of abdomen from 2017, bilateral adrenal
lesions measuring <1 cm were noted. ACTH-independent
mild autonomous cortisol secretion was confirmed with
1 mg overnight dexamethasone suppression test, which
failed to suppress cortisol (2.9 mcg/dL), along with suppressed baseline ACTH and DHEAS. Plasma fractionated

metanephrines, plasma renin activity, and plasma aldosterone concentration were normal (Table 1). Because there
were bilateral nodules, AVS was pursued to differentiate
between a bilateral versus unilateral source of cortisol excess prior to planning surgical intervention (Table 2). Due
to concerns of cortisol excess confounding interpretation
of AVS results, metanephrine levels were used to ascertain
proper catheterization. Dekkers et al [22] has suggested
that the AV:PV metanephrine ratio should be >12 if there is
adequate catheterization. As shown in Table 2, the AV:PV
ratio was 60 on the right and 24.5 on the left for this patient. Cortisol was detected from both sides, 24 μg/dL from
the right, and 37.4 μg/dL from the left, demonstrating that
there was not a predominant cortisol-producing nodule
that was suppressing the contralateral side (cortisol gradient < 2). However, the cortisol to metanephrine ratio
was 7.6 on the left, and 2.0 on the right. The left to right
cortisol to metanephrine ratio of 3.8 was suggestive of
dominant left side cortisol production. Hence, a decision
to pursue unilateral left adrenalectomy was taken and
the patient underwent a successful left adrenalectomy in
September 2019. An ACTH stimulation test 1 week following surgery showed cortisol levels of 14.7, 21, and 19.1
mcg/dL at baseline, 30 minutes, and 60 minutes, respectively. After surgery, she was started on a physiologic dose
of hydrocortisone. Four weeks post-adrenalectomy, blood
pressure was controlled and her lisinopril was stopped. She
lost approximately 6 pounds within 3 months after surgery and continued to remain normotensive without any
antihypertensive. Hydrocortisone was gradually tapered
off over 5 months post-adrenalectomy, as early discontinuation resulted in symptoms of nausea, abdominal

Table 1. Biochemical Studies Confirming Autonomous Cortisol Secretion From Adrenal Gland Before Surgery and
Improvement After Surgery[1, 2, 18, 21]
Diagnostic Workups (Reference Interval)

1-mg overnight dexamethasone suppression test
Cortisol (<1.8 mcg/dL) [21]
(Serum dexamethasone level 140 – 295 ng/dL)
4-mg dexamethasone suppression test for AVS, cortisol (mcg/dL)
24-hour urine free cortisol (< 90 mcg per day) [18]
Plasma ACTH level (9 – 52 pg/mL) [18]
Plasma DHEAS level (35-430 mcg/dL)
Late-night salivary cortisol (< 0.145 mcg/dL) [1] or (< 0.17 mcg/
dL) [2]
Aldosterone level (normal 3-16 ng/dL)
Plasma renin activity (0.25 – 5.82 ng/mL/h)
Free normetanephrine/metanephrine (< 0.9/0.5 nmol/L)

Results
Before Surgery

After Surgery

2.9 (293), 3.3 (311)
6 and 7 months before surgery

< 2 (329), 1.1 (370)
6 and 12 months after surgery

2.9
35
6, < 5
32, 32
0.069, 0.070

17.5, 17.8
26, 23
0.098

<1
0.19
0.38/<0.20

Abbreviations: ACTH, adrenocorticotropic hormone; AVS, adrenal venous sampling; DHEAS, dehydroepiandrosterone sulfate; NA, not applicable.
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catecholamines in nondominant adrenal vein]) to determine the lateralization of cortisol secretion. We measured
the cortisol to catecholamines lateralization ratio in comparison with cortisol, cortisol/aldosterone, and cortisol/
dehydroepiandrosterone sulfate (DHEAS) lateralization
ratio. Patients were deemed to have an acceptable response
to unilateral adrenalectomy if they developed adrenal insufficiency after unilateral adrenalectomy, serum cortisol
less than 2 mcg/dL after dexamethasone suppression test,
or improved clinically (hypertension, obesity, and diabetes).
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Table 2. Results of Adrenal Venous Sampling After 4-mg Overnight Dexamethasone Suppression
Venous blood source

Normetanephrine
nmol/L

Cortisol
nmol/L

Aldosterone
nmol/L

8.2

662

1.50

4.9

3.7

1031

<0.028

<0.2

< 0.2

12

80

0.194

Cortisol/
Cortisol
lateralization metanephrine
ratio
ratio

Cortisol/
metanephrine
lateralization ratio

1.558

3.8

55.2
210.4

NA

NA

NA

Abbreviations: AV, adrenal veins; AVS, adrenal venous sampling; NA, not applicable; PV, peripheral veins.
AV:PV metanephrine ratio > 12 indicates correct adrenal vein position and successful catheterization [22].
AV:PV cortisol gradient distinguishes cortisol-producing conditions. The gradient ≤3.3 suggests nonsecretory adenoma, between 4.1 and 6.4 is associated with
adrenal hyperplasia, and >6.5 is consistent with adrenal adenoma [17, 18].
A side-to-side (high-side to low-side) adrenal vein cortisol gradient (cortisol lateralization ratio) >2.3 suggests unilateral cortisol overproduction, while a gradient ≤2.0 is considered as bilateral overproduction [17, 21]. However, the lateralization is toward the left adrenal nodule, based on the nodule size and cortisol/
metanephrine ratio gradient.

pain, and diarrhea. After weaning off the hydrocortisone,
an overnight 1 mg dexamethasone suppression test was
normal (Table 1). A follow up CT scan of her abdomen in
December 2019 showed a mild increase in size of the right
adrenal nodule, from 2.3 cm in maximum dimension to
3 cm in maximum dimension, but the size remained stable
at 3 cm in September 2020.

Discussion
This patient had SCS with bilateral adrenal nodules along
with hypertension and obesity. She improved clinically and
biochemically with unilateral adrenalectomy. SCS management poses a challenge, especially in the setting of bilateral
adrenal mass. It is important to solve the puzzle of which
adrenal gland should be removed and avoid permanent adrenal insufficiency secondary to bilateral adrenalectomy or
surgical removal of the wrong adrenal.
The first step in the workup is confirmation of autonomous cortisol production. This can be challenging because
patients with SCS do not demonstrate the clear and continuous high cortisol production typical of Cushing syndrome. For example, the absence of a diurnal rhythm of
cortisol production is consistent with autonomous cortisol production from Cushing syndrome [23], specifically
Cushing disease [24] and can be assessed by measuring
midnight salivary cortisol, midnight serum cortisol, or
urine free cortisol [2]. However, the evaluation of altered
circadian rhythm of cortisol in the setting of autonomous production is not sensitive for detection of SCS [2,
25, 26]. The late-night salivary cortisol is more sensitive
for detecting Cushing syndrome [27]. The measurement
of urine free cortisol does not appear to be a sensitive
screening test for SCS [2], since the increased cortisol

production in SCS does not usually exceed the binding
capacity of plasma for cortisol leading to urine free cortisol that is typically normal [2, 7].
The atrophy of contralateral adrenal gland in the
setting of unilateral cortisol-producing adenoma is
a relatively well-known event due to the decrease in
ACTH production [28]. Applying techniques such as
multidetector CT [28], cholesterol scintigraphy [13, 21,
29, 30], or PET-CT using 18F-FDG [14, 31], may help
lateralizing the cortisol-producing adenoma in a patient
with bilateral adrenal mass. However, contralateral atrophy does not necessarily happen in patients with SCS.
In addition, suppression of ACTH may lead to reduction
in size of a contralateral cortisol-producing adenoma and
hence create the appearance of a unilateral tumor on CT
imaging, but with bilateral overproduction of cortisol.
Ueland et al reported 9 patients with unilateral nodule
on CT scan who had had bilateral cortisol production
after AVS study [21].
Generally, AVS provides useful information to lateralize
the source of cortisol production. However, we may face
some limitations, which requires better understanding of
AVS pitfalls, to avoid unnecessary adrenalectomy. Acharya
et al reported 8 cases with ACTH-independent Cushing syndrome with bilateral adrenal masses and successful catheterization showed a cortisol lateralization ratio ≤ 2 in 7 cases,
suggesting bilateral cortisol overproduction. However, 3 of
8 patients underwent unilateral adrenalectomy based on
size of adrenal lesion and remission was seen in 1 case [16].
These data suggest that AVS is the best method for
lateralizing the source of cortisol-producing adenoma
but the current lateralizing criteria might not detect
unilateral autonomous cortisol production in certain situations. Hypothetically, the proximity of the
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Right AV
2.3 cm nodule
Left AV
3.5 cm nodule
PV (femoral vein)

Metanephrine
nmol/L
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stress during intervention [33, 44] on cortisol secretion
by suppressing ACTH.
Based on our case experience and literature review
(Table 3), we propose an algorithm taking into consideration cortisol to metanephrine ratio for selecting candidates for unilateral adrenalectomy (Fig. 1). Patients with
unilateral adenoma and contralateral adrenal atrophy in
the setting of clinical and paraclinical findings suggestive
for SCS should receive unilateral adrenalectomy after considering the benefits and risks of surgical intervention. If a
patient has bilateral adenoma, then AVS is the best method
to confirm the source of cortisol production and avoiding
unnecessary surgery. An AV:PV metanephrine ratio > 12
suggests successful catheterzation. An AV:PV cortisol gradient > 6.5 is consistent with cortisol-producing adenoma
and a high to low cortisol gradient > 2.3 is compatible
with unilateral cortisol-producing adenoma [17, 21, 33].
If the AV:PV cortisol gradient is < 6.5 or high to low cortisol gradient is < 2.3, we suggest measuring high to low
cortisol/metanephrine ratio gradient. High to low cortisol/metanephrine ratio gradient > 2.3 suggests unilateral
cortisol-producing adenoma. The proximity of the catheter
to adrenal gland is a possible reason for the dilution differences and cortisol to metanephrine ratio may help to
correct the dilution differences. Cosrtisol to aldosterone
ratio [33] or cortisol to androrgen [38] ratio may also help
lateralizing the source of cortisol production but because
of the co-secretion of other hormones [32], which can affect the concentration of cortisol, aldosterone, and other
plama steroids, making the interpretation of lateralization
more difficult. However, the co-secretion of metanephrine
and cortisol form an adrenal adenoma is rare [45-48] and
associated pheochromocytoma can be ruled out with serum
and 24-hour urine measurements. In addition, the current
algorithm (Fig. 1) is based on limited experience with a few
patients and needs validation in a bigger study.

Conclusion
AVS sampling is the best method to lateralize the source of
cortisol production in SCS patients with suspected bilateral
nodules or sources of cortisol. In certain situations, if the
cortisol lateralization ratio does not help in lateralization of
cortisol hypersecretion, then the cortisol to metanephrine
ratio would be another option to find the major source of
cortisol production and provide an option for unilateral
adrenalectomy.
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catheter to the adrenal gland and co-secretion of other
hormones, such as aldosterone and DHEAS, can affect cortisol concentration [17, 32]. The usual method
to correct the dilution changes is using the ratio of
cortisol to aldosterone, DHEAS, or catecholamines
[33]. However, co-secretion of aldosterone and cortisol from different adrenals [34, 35] or same adrenal
gland [32] can affect the result of the cortisol to aldosterone ratio. In addition, the incidence of adenoma
with co-secretion of cortisol and aldosterone may be
higher than earlier thought [36, 37]. Furthermore, AVS
results showed that cortisol secretion from adrenal vein
of patients without autonomous cortisol secretion has
variation. Even measurement of the adrenal androgens,
androstenedione and DHEA, may help in correcting the
side-to-side gradient [38], but co-secretion of androgens in the SCS patient [32] will potentially interfere
with this correction. The benefits of using catecholamine for correction is more important (Table 3), as
co-secretion of aldosterone and other steroids [32] precludes applying the cortisol to aldosterone or cortisol
to DHEAS ratio for interpreting the AVS outcomes.
In addition, the shorter half-life of aldosterone (20
minutes) versus that of cortisol (60-70 minutes) is a
limitation [33]. However, half-life for the fractionated
metanephrines (60-105 minutes for free metanephrine,
and 95 minutes for normetanephrine) [39] is longer
than aldosterone and comparable to cortisol (60-70
minutes) [33]. Furthermore, with metanephrine and
normetanephrine, especially metanephrine, plasma
levels are less responsive to sympathoadrenal stimulation [40]. Other catecholamines, such as adrenaline
and noradrenaline, have shorter half-lives (just a few
minutes) [39, 41] and are not good options for overcoming the dilution changes of cortisol concentration.
It is important to mention that pheochromocytoma alters the cortisol concentration [42] and co-secretion
of catecholamines with cortisol may happen in the
setting of an ACTH- or corticotropin-releasing hormone–producing pheochromocytoma [43], which is a
rare condition that can easily be identified during biochemical workup for adrenal incidentaloma detectable
by measuring fractionated catecholamines and ACTH.
Therefore, side-to-side cortisol to metanephrine ratio
comparison is useful for lateralization, because of the
possible changes in concentration of cortisol during the
AVS. We must also consider that applying dexamethasone before intervention can diminish the effect of

1.53 R to L ratio

1.99 R to L ratio

1.28 L to R ratio

3. Case
8

4. Case
9

5. Case
10

0.86 L to R ratio
1.16 R to L ratio

3.6 Cortisol/
noradrenaline,
4.2 Cortisol/adrenaline
12.5 Cortisol/
noradrenaline,
330 Cortisol/
adrenaline
2.6 Cortisol/
noradrenaline,
2.1 Cortisol/adrenaline
2.6 Cortisol/
noradrenaline,
2.6 Cortisol/adrenaline
1.44 Cortisol/
noradrenaline,
2.7 Cortisol/adrenaline
5.18 Cortisol/
epinephrine
2.1 L to R Cortisol/
epinephrine
0.5 R to L Cortisol/
epinephrine

Cortisol/catecholamine
lateralization ratio

1.5

1.28

0.82

0.97

NA

1

1.1

NA

1.6

7.1

NA

1.5

2.6

4

Cortisol/DHEAS
lateralization ratio

Cortisol/aldosterone
lateralization ratio

Right side adrenalectomy for PA and left side adrenalectomy for
SCS, adrenal insufficiency after second left side adrenalectomy
Left adrenalectomy, AIMAH (left adrenal mass 3.1 × 2.5 cm,
right adrenal nodule 1.2 × 1.9 cm)
improvement of blood pressure, but no satisfactory effects on
blood sugar and lipid profile

Bilateral adrenalectomy, PPNAD, with normal CT

Bilateral adrenalectomy, PBMAH with bilateral nodules,
CT Bilaterally enlarged adrenal glands (R 50 × 47, L
41 × 32 mm)
Bilateral adrenalectomy, PPNAD, with normal CT

Adrenal insufficiency after right unilateral adrenalectomy,
adrenal adenoma,
CT Bilateral adrenal incidentaloma (R 32 × 18, L 14 × 8 mm)
Adrenal insufficiency after left unilateral adrenalectomy, adrenal
adenoma,
CT Bilateral adenomas (R 22 × 15, L 64 × 50 mm)

Outcomes
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Listed in reverse order of the year of publication [18, 33, 34].
The cortisol/catecholamine ratio is sometimes a better method to detect the source of cortisol production (Number 1, 2, and 7). The cortisol/aldosterone ratio and cortisol/DHEAS ratio are less sensitive than cortisol/catecholamine ratio in lateralizing the source of cortisol production.
Abbreviations: AIMAH, adrenocorticotropin independent macronodular adrenocortical hyperplasia; ACTH, adrenocorticotropic hormone; AVS, adrenal venous sampling; DHEAS, dehydroepiandrosterone sulfate; L, left;
NA, not available; PBMAH, primary bilateral macronodular adrenal hyperplasia; PPNAD, primary pigmented nodular adrenocortical disease; R, right.

Maghrabi
et al. [18]

4.62 L to R ratio

1.65 L to R ratio

2. Case
7

6. Case
1
7. Case
1

2.5 R to L ratio

1. Case
1

Papakokkinou
et al. [33]

Lee et al. [34]

Cortisol
lateralization ratio

Patient

Reference

Table 3. AVS Results of the Patients With Cortisol-Producing Adenoma and Comparison of Cortisol/Catecholamine Lateralization Ratio With Other Ratio From the Literature
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Figure 1. Proposed algorithm for diagnosis and confirmation of the source of cortisol-producing adenoma in subclinical Cushing syndrome (SCS)
patients with adrenal incidentaloma (ACTH-independent cortisol secretion) [17, 18, 21, 22, 28]. First, it is important to confirm ACTH-independent
SCS [1, 2]. Second, the source of excess cortisol production should be investigated by CT or AVS, when CT is not definitive [21, 28]. AVS results need
interpretation, including confirmation of correct catheterization [22] and the presence of unilateral cortisol production based on the current evidence
[17, 18, 21]. If using the current criteria for laterlaizing the source of cortisol production was not successful, then the cortisol/metanephrine ratio
can be used to avoid unnecessary bilateral adrenalectomy, which is associated with increased mortality [16]. Abbreviations: ACTH, adrenocorticotropic hormone; AV, adrenal vein; CT, computed tomography; DHEAS, dehydroepiandrosterone sulfate; DST, dexamethasone suppression test; HPA,
hypothalamic-pituitary-adrenal; PV, peripheral vein; SCS, subclinical Cushing syndrome; UFC, urine free cortisol.
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